Gamma Tile-Surgically Targeted Radiation Therapy (STaRT)

DEVICE2 trials

Sponsors

GT Medical Technologies, Inc.

Conditions

Brain MetastasesGlioblastoma

Phase 3

Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)

Active, not recruitingNCT04365374

GT Medical Technologies, Inc.Brain Metastases

Start: 2021-04-06End: 2029-08-30Target: 230Updated: 2025-10-07

Phase 4

Post-operative Adjuvant Therapy w/wo GammaTile + Systemic Therapy

WithdrawnNCT05900908

GT Medical Technologies, Inc.Glioblastoma

Start: 2025-05-31End: 2028-06-30Updated: 2025-04-10

Related Papers

Early Experience and Perioperative Risk of GammaTile® for Upfront Brain Metastases: Report from a Prospective Multicenter Study

Neuro-Oncology Advances2024-09-10

A phase 3 randomized controlled trial of post-surgical stereotactic radiotherapy versus surgically targeted radiation therapy with GammaTile for treatment of newly diagnosed metastatic brain tumors.

Journal of Clinical Oncology2024-06-01

Dosimetric Impacts of Source Migration, Radioisotope Type, and Decay with Permanent Implantable Collagen Tile Brachytherapy for Brain Tumors

Technology in Cancer Research & Treatment2022-01-0111 citations

Clinical Trials in Progress: ROADS Trial

ONCOLOGY2021-08-014 citations

A phase III multicenter randomized controlled trial of postsurgical stereotactic radiotherapy versus surgically targeted radiation therapy (STaRT) for the treatment of large (>2.5cm) newly diagnosed brain metastases: Trial in progress.

Journal of Clinical Oncology2021-05-20